美洲 · 股市与财经 · BNN Bloomberg
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company…
在 BNN Bloomberg 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.bnnbloomberg.ca)
